Open AccessPatient Outcomes on Day 4 of Intravenous Antibiotic Therapy in Non–Intensive Care Unit Hospitalized Adults With Community-Acquired Bacterial Pneumonia
Author(s) -
Scott B. Robinson,
Frank R. Ernst,
Craig Lipkin,
Xingyue Huang
Publication year - 2014
Publication title -
infectious diseases in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 21
eISSN - 1536-9943
pISSN - 1056-9103
DOI - 10.1097/ipc.0000000000000143
Subject(s) - medicine , demographics , pneumonia , intensive care unit , community acquired pneumonia , antibiotics , emergency medicine , intensive care medicine , pediatrics , demography , sociology , microbiology and biotechnology , biology
Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality especially in hospitalized patients. In place of clinical end points traditionally used to evaluate antimicrobial efficacy for its treatment, Food and Drug Administration guidelines now require all registration trials to assess clinical response at day 4. The primary objective of this study was to assess health outcomes (length of stay [LOS] and hospital charges) between responders and nonresponders at this time point.